Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sensitivity of Pharmacokinetics to Differences in the Particle Size Distribution for Formulations of Locally Acting Mometasone Furoate Suspension-Based Nasal Sprays.

Molecular pharmaceutics·2023
Same author

Central and peripheral lung deposition of fluticasone propionate dry powder inhaler formulations in humans characterized by population pharmacokinetics.

Pharmaceutical research·2023
Same author

Mechanistic modeling of generic orally inhaled drug products: A workshop summary report.

CPT: pharmacometrics & systems pharmacology·2022
Same author

Correction to: Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?

The AAPS journal·2021
Same author

Optimization of the Transwell<sup>®</sup> System for Assessing the Dissolution Behavior of Orally Inhaled Drug Products through In Vitro and In Silico Approaches.

Pharmaceutics·2021
Same author

Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?

The AAPS journal·2021

Related Experiment Video

Updated: Jul 15, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Advances in single-entity inhaled corticosteroid therapy.

Zia R Tayab1, Günther Hochhaus

  • 1Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, Florida, USA.

Allergy and Asthma Proceedings
|May 8, 2007
PubMed
Summary

Inhaled corticosteroid (ICS) therapy aims for targeted lung effects with minimal side effects. Ideal ICS compounds feature high lung deposition, rapid clearance, and sustained action for improved safety and efficacy.

Related Experiment Videos

Last Updated: Jul 15, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Drug Delivery

Background:

  • Inhaled corticosteroid (ICS) therapy is crucial for managing respiratory conditions.
  • Optimal ICS therapy requires balancing pulmonary efficacy with minimal systemic side effects.
  • Key pharmacokinetic and pharmacodynamic properties influence ICS safety and effectiveness.

Purpose of the Study:

  • To outline the ideal characteristics of inhaled corticosteroids (ICS) for optimal drug targeting.
  • To discuss how pharmacokinetic and pharmacodynamic properties contribute to a favorable safety and efficacy profile.
  • To highlight recent advancements and future directions in ICS development.

Main Methods:

  • Review of pharmacokinetic and pharmacodynamic principles relevant to ICS.
  • Analysis of ideal properties including deposition, clearance, bioavailability, residence time, receptor binding, and protein binding.
  • Discussion of recent developments in ICS compounds and potential improvements in delivery devices and formulations.

Main Results:

  • Ideal ICS possess high pulmonary deposition, high systemic clearance, low oral bioavailability, sustained pulmonary residence, selective receptor binding, and high plasma protein binding.
  • Recent ICS developments have focused on these characteristics, leading to compounds with a high therapeutic index.
  • Improvements in delivery devices and formulations may further enhance pulmonary residence time.

Conclusions:

  • Achieving optimal drug targeting with ICS requires specific pharmacokinetic and pharmacodynamic properties.
  • Current ICS therapies have advanced significantly, offering improved safety and efficacy.
  • Future research should focus on delivery systems and formulations to further optimize ICS therapy.